Infinium Pharmachem Ltd
Incorporated in 2003, Infinium Pharmachem Ltd manufactures and sells Iodian based Pharmaceutical Intermediates[1]
- Market Cap ₹ 446 Cr.
- Current Price ₹ 286
- High / Low ₹ 324 / 189
- Stock P/E 36.7
- Book Value ₹ 77.7
- Dividend Yield 0.00 %
- ROCE 12.2 %
- ROE 10.5 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 14.0% over last 3 years.
- Promoter holding has decreased over last 3 years: -8.14%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of Nifty SME Emerge
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| 39 | 71 | 99 | 114 | 136 | 156 | 190 | |
| 36 | 66 | 89 | 98 | 117 | 136 | 168 | |
| Operating Profit | 2 | 5 | 10 | 16 | 19 | 19 | 22 |
| OPM % | 6% | 7% | 10% | 14% | 14% | 12% | 11% |
| 1 | 1 | 1 | 1 | 2 | -1 | 2 | |
| Interest | 1 | 1 | 2 | 3 | 2 | 4 | 3 |
| Depreciation | 1 | 1 | 1 | 1 | 3 | 3 | 3 |
| Profit before tax | 1 | 4 | 9 | 13 | 15 | 12 | 18 |
| Tax % | 30% | 28% | 23% | 24% | 24% | 32% | 20% |
| 1 | 3 | 7 | 10 | 12 | 8 | 14 | |
| EPS in Rs | 0.93 | 2.72 | 6.11 | 9.30 | 8.12 | 5.23 | 7.80 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 22% |
| 3 Years: | 18% |
| TTM: | 22% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 35% |
| 3 Years: | 9% |
| TTM: | 21% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 5% |
| 1 Year: | 13% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 18% |
| 3 Years: | 14% |
| Last Year: | 11% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 5 | 14 | 16 | 16 |
| Reserves | 3 | 6 | 12 | 17 | 45 | 94 | 105 |
| 9 | 11 | 23 | 29 | 11 | 52 | 23 | |
| 9 | 17 | 23 | 19 | 15 | 37 | 31 | |
| Total Liabilities | 22 | 34 | 59 | 71 | 85 | 198 | 175 |
| 4 | 5 | 4 | 19 | 20 | 24 | 23 | |
| CWIP | 0 | 4 | 8 | 0 | 0 | 1 | 8 |
| Investments | 0 | 0 | 0 | 0 | 0 | 29 | 29 |
| 18 | 26 | 46 | 52 | 66 | 144 | 114 | |
| Total Assets | 22 | 34 | 59 | 71 | 85 | 198 | 175 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| 3 | 7 | 12 | 9 | -13 | -29 | 34 | |
| -1 | -5 | -7 | -5 | -4 | -27 | -7 | |
| -1 | -1 | -2 | -3 | 23 | 79 | -32 | |
| Net Cash Flow | 1 | 1 | 3 | 1 | 6 | 23 | -5 |
| Free Cash Flow | 2 | 2 | 7 | 1 | -17 | -38 | 24 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 137% | 168% | 137% | 73% | -51% | -131% | 173% |
Ratios
Consolidated / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 75 | 59 | 57 | 49 | 55 | 79 | 61 |
| Inventory Days | 84 | 62 | 78 | 89 | 87 | 137 | 96 |
| Days Payable | 82 | 79 | 56 | 31 | 16 | 38 | 10 |
| Cash Conversion Cycle | 76 | 43 | 78 | 108 | 126 | 178 | 146 |
| Working Capital Days | 46 | 12 | 25 | 27 | 96 | 97 | 99 |
| ROCE % | 32% | 38% | 36% | 28% | 15% | 12% |
Insights
In beta| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2026 | |
|---|---|---|---|---|---|---|---|
| Export Revenue Share % ・Standalone data |
|
||||||
| Number of Customers count ・Standalone data |
|||||||
| Production Volume MT ・Standalone data |
|||||||
| EU-REACH Registrations (Approved) count ・Standalone data |
|||||||
| Number of APIs count ・Standalone data |
|||||||
| Number of Iodine Derivatives count ・Standalone data |
|||||||
| Installed Capacity MTPA ・Standalone data |
|||||||
| Top 5 Customers Revenue Share % ・Standalone data |
|||||||
Extracted by Screener AI
Documents
Announcements
-
Certificate under SEBI (Depositories and Participants) Regulations, 2018
- Regulation 74(5) certificate for quarter ended September 30, 2026; shares fully dematerialized, no rematerialisation requests.
-
Integrated Filing- Governance
- SME-listed Infinium Pharmachem says Q2 FY27 corporate governance report not applicable; complaints status NIL.
-
Updates
- Submitted annual secretarial compliance report dated September 29, 2026 for NSE main-board migration.
-
Shareholders meeting
- Postal ballot resolution under Regulation 277 passed on 28 Sep 2026.
-
Trading Window
- Trading window closed from October 1, 2026 until 48 hours after H1 FY2026 results.
Annual reports
-
Annual Report 2026
from nse
-
Annual Report 2025
from nse
-
Annual Report 2024
from nse
-
Annual Report 2023
from web
Concalls
-
Nov 2025PPT
-
Jun 2024Transcript PPT REC
-
Mar 2024Transcript PPT
Business Overview:[1]
IPL is a GMP compliant, FDA Approved and ISO 9001-2015 certified coimpany which does development, manufacture, and export of Iodine Derivatives & API. Currently, it has 250+ intermediates and 15+ APIs. It supplies a range of Iodine derivatives on Order to Made basis